Eylea Reaches 2,000 Patients Since Bayer-Santen Japan Launch
This article was originally published in PharmAsia News
Executive Summary
Approximately 2,000 patients have used vascular endothelial growth factor inhibitor Eylea (aflibercept), a drug for the treatment of exudative age-related macular degeneration, after the product was launched by Bayer Pharmaceuticals and Santen Pharmaceuticals just over a month ago on Nov. 27, 2012.